Objective: Overall survival (OS) for advanced stage (IIIA-IV) non-small cell lung cancer (NSCLC) is highly variable, and retrospective data show a survival advantage for patients receiving therapeutic intent pulmonary resection. We hypothesized that this variability in OS can be modeled separately by stage to allow a personalized estimate of OS.
Patients who undergo lung resection live longer than those treated nonsurgically.
Central Message
When patients with advanced-stage NSCLC are treated with surgery, they live longer. This analysis demonstrates that this finding is not purely selection bias.
Perspective
We used a prediction model to assess the therapeutic impact of lung resection on overall survival. We demonstrate that across all stages, the hazard of death is twice as high in patients not treated surgically compared with surgically treated patients. Our model can be used to identify patients who have the greatest probability of benefiting from lung resection and to identify patients for whom lung resection has minimal opportunity to improve survival.
See Commentaries on pages 1629 and 1631.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the United States. 1 Overall 5-year survival is approximately 18%, but for patients with advanced-stage (stages IIIA, IIIB, or IV) NSCLC, it is particularly poor. Importantly, however, survival rates for these subgroups are quite variable.
Depending on factors such as stage of disease and treatment modality, 5-year survival ranges from 4% to 28%. 2 The heterogeneity of the clinical, pathologic, and facility characteristics of these patients likely accounts, in part, for the variable survival outcomes among these patients, but these same variable characteristics also have been implicated as the foundation of widely disparate treatment approaches. 2, 3 Moreover, it is these patients with advanced stage who make up the vast majority of patients with NSCLC, representing roughly 79% of newly diagnosed patients, so reduction in treatment variation and/or risk stratification is anticipated to translate to significant therapeutic gains. 1 Current National Comprehensive Cancer Network guidelines only recommend therapeutic intent surgical treatment for patients with stage IIIA disease who have single-station nodal disease or stage IV patients with oligometastatic disease to the brain or adrenal glands. 4 Despite this limited recommendation for surgical treatment, several series have demonstrated a clinically and statistically significant survival advantage for patients treated surgically compared with patients treated nonsurgically. 3, 5, 6 However, uniformly, the analyses demonstrating a survival advantage with surgery are retrospective in nature, and the survival advantages observed are typically attributed to selection bias in the surgical cohorts. 3, 5, 6 An accepted approach to control for selection bias in retrospective analyses is to use statistical methodology such as propensity matching to control for confounding variables. However, this technique is limited by the inability to assess unmeasured confounders such as severity of comorbidities and disease burden. 7 In addition, these techniques are typically limited to retrospective analyses of outcomes and do not directly assist with prospective treatment decision-making. 5, 6 In an effort to improve data-driven treatment decision making for these patients, we recently developed a Surgical Selection Score (SSS) to explore factors inherent in the selection for surgical treatment among advanced-stage NSCLC. 8 One distinct advantage of the SSS over propensity matching is that it can be used in a prospective manner when treatment decisions are being made. The SSS was created in a population cohort from patients with advanced-stage NSCLC in the National Cancer Database (NCDB) using a logistic regression model that predicts likelihood of selection for surgery based on clinical factors available at the time of treatment decisions. The factors included in the SSS are all clinical, including histology, tumor size, American Joint Committee on Cancer (AJCC) clinical T status, AJCC clinical N status, AJCC clinical M status, Charlson comorbidity index, age, race, facility type, insurance, and income, with AJCC clinical M status, AJCC clinical N status, and age having the strongest influence on selection for surgery. In the current analysis, our objectives were to define the stage-specific ability of the SSS to predict overall survival (OS) for patients with advancedstage NSCLC to assess the impact of surgery in patients at same stage and comparable SSS and to provide a risk assessment tool.
METHODS
Using the NCDB Participant User File from 1998 to 2012, we identified cases of biopsy-proven NSCLC. The NCDB is a joint program of the Commission on Cancer and the American Cancer Society. 9 Data from the NCDB represent 1500 Commission on Cancer-accredited facilities including more than 70% of all newly diagnosed cancer cases in the United States. Standard patient, tumor, and treatment data were extracted and categorized as appropriate. Patients were categorized into surgical and nonsurgical groups. Nonsurgical treatments included chemotherapy only, chemotherapy and radiation, radiation only, and no treatment. Surgical treatments included surgery only; chemotherapy and surgery; chemotherapy, radiation, and surgery; and surgery and radiation. Surgical operations included wedge resection, sublobar resection, lobectomy, bilobectomy, and pneumonectomy in an attempt to focus our analysis on therapeutic intent procedures aimed at resection of the primary tumor.
Patient comorbidities were assessed using the Charlson comorbidity index, described by Deyo and colleagues. 10 Additional categorical variables examined included clinical tumor group, clinical T group, clinical N group, clinical M group, histology, age, sex, race, income, education, insurance status (Medicaid, Medicare, other government, private health insurance, no insurance), and treatment facility. Age was categorized by percentile (10th, 25th, 50th, 75th, 90th). Income categories were defined as follows: low $38,000; middle >$38,000-47,999, and high $48,000.
Statistical Analyses
As we have previously described, logistic regression was used to create the SSS with the outcome variable representing inclusion of surgery in the treatment regimen. 8 The SSS was created by a linear rescaling of the logarithm of the odds ratio of inclusion of surgery in the treatment regimen to generate a single numeric value between 0 and 1200 for each patient depending on the value of the clinical factors for each patient. In the current analysis, the ability of the SSS to predict OS was assessed using the Cox proportional hazards model with SSS as the only explanatory variable, for the entire cohort and separately by stage. Discrimination ability was measured by calculating an overall C-index (concordance index) for the Cox model. 11, 12 The C-index was introduced by Harrell as a natural extension of the area under the receiver operator curve from logistic regression. 13 The C-index is defined as the proportion of all usable patient pairs in which the predictions and outcomes are concordant. The overall C-index and confidence interval (CI) hereof for survival analysis where censoring is an issue was calculated as proposed by Pencina and D'Agostino. 11, 12 OS were illustrated and median survival times calculated using a Kaplan-Meier life table approach and compared by log-rank test. For
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comparison of which variables are most important in terms of predicting surgical treatment versus survival, a Cox Model was fitted using all the predictors used to create the SSS but not the SSS itself. Distribution of the SSS and the Kaplan-Meier estimate of 3-year survival were visually illustrated for each stage by treatment category (surgical vs nonsurgical) and within each stage the mean values of SSS were statistically compared for the 2 treatment categories. To assess the potential benefit of surgery for patients with high SSS (above approximately the 75% percentile), the overall effect of surgery on the hazard of death was estimated for these patients by the Cox model separately by stage. These models were further adjusted for SSS by categorizing into small subgroups each representing 5% of the top quartile. P values less than .05 were considered statistically significant. All statistical analyses were conducted using SAS, version 9.4 (SAS Institute Cary, NC). This study received a determination letter from the University of California, Davis Institutional Review Board.
RESULTS
We identified 300,572 patients with biopsy-proven stage IIIA, IIIB, or IV NSCLC from the NCDB (Figure 1) . Notably, 18,701 (6.2%) of these patients had surgery as part of their treatment regimen. In total, 265,183 patients had survival data available for follow-up for use in Cox proportional hazards model. The patients with missing survival information were evenly distributed across the surgery and nonsurgery groups and SSS. As previously reported, the strongest predictors of selection for surgery were AJCC clinical metastatic group, AJCC clinical nodal group, and age. 8 The strongest predictors affecting the hazard of death were AJCC clinical metastatic group and age (Table 1) .
In Cox proportional hazards model, SSS was highly predictive of OS ( Table 2 ). The C-index for a model based on the entire cohort was 0.89, and predictive ability increased when each stage group was considered separately. OS was also significantly greater in the surgically treated patients across all stage groups (P<.001) (Figure 2) , with median survival times for surgical patients about 3-fold longer (Table 3) . Within each stage, surgical patients show both greater values of SSS (within each stage, mean values for SSS are significantly different between the surgical and nonsurgical group with P <.0001) and a greater probability of 3-year survival than their nonsurgical counterparts ( Figure 3) .
A substantial number of nonsurgical patients, however, have high SSS values, comparable with the surgical group. We assessed the potential impact of surgery on the hazard of death using the Cox model separately by stage, restricting analysis to approximately the upper quartile of SSS (900 for stage IIIA, 800 for stage IIIB, 700 for stage IV) and adjusting for narrowly defined SSS categories. Within this group, across all stages, the hazard rate was at least 2 times greater for patients not treated surgically compared with patients with similar SSS who received surgical treatment. The hazard ratios (HR) were stage IIIA: HR, 2.1; 95% CI, 2.0-2.2, stage IIIB: HR, 2.3; 95% CI, 2.2-2.5, and stage IV: HR; 2.3; 95% CI, 2.2-2.4.
DISCUSSION
Using clinical, demographic, and pathologic variables, we have created a novel prediction score that estimates the probability of surgical treatment and OS accurately in advanced-stage NSCLC. Across all stages, there is a meaningful survival advantage for surgical patients. The SSS uses the AJCC staging system variables supplemented by selected clinical variables that are available at the time of treatment decisions to estimate probability of surgical treatment and survival in a stage-specific manner. It has excellent discriminatory capabilities, as shown by C-indices approaching 1 for both the outcomes described in our previous publication and in the current analysis. In the current analysis, we defined the stage-specific ability of the SSS to predict OS for patients with advanced-stage NSCLC and assessed the impact of surgery in patients with same stage and very comparable high SSS in an attempt to mitigate the influence of selection bias. Our data support a therapeutic effect of surgery for at least some of these patients beyond what can be explained by selection bias, given the high precision of the SSS to predict surgical treatment and the improved OS in surgical patients at comparable high SSS. In our view, these findings warrant further investigation to understand the potential favorable effects of surgery in appropriately selected patients with advanced-stage NSCLC. As mentioned previously, there are data to suggest improved survival in patients with advanced-stage NSCLC who undergo pulmonary resection. A recent study using NCDB data that reflected treatments given for stage IIIA NSCLC from 1998 to 2010 demonstrated a low incidence of pneumonectomy (16%) and superior survival outcomes for surgical patients who were matched to nonsurgical patient using demographic variables (median survival 35.9 for trimodality patients vs 19.7 months for chemotherapy and radiation patients, P <.001). 6 In a study of stage IIIB patients using data from the SEER database for 2004 to 2012, median OS was 29 months in patients treated with surgery and radiation compared with only 11 months in patients treated with radiation alone (P <.0001). Similarly, Bateni and colleagues 15 found that lung resection in patients with stage IV cancer is safe and associated with similar 30-day mortality and serious morbidity when compared with patients without disseminated malignancy in the American College of Surgeons National Surgical Quality Improvement Program dataset. Although these studies attempted to control for selection bias with statistical techniques, similar to ours, they are limited by their retrospective nature and inability to assess for confounding variables that are not captured in these large datasets. 7 Despite these limitations, there are significant differences in the OS trends in these series compared with the earlier randomized trials, reinforcing the concept that improvements in staging and multimodality therapies, including surgical outcomes, may identify a small subset of advanced-staged patients who may benefit from surgical management. In concert with these data, the SSS is applicable to each of stage IIIA, IIIB, and IV NSCLC patients and continues to highlight the potential benefit of including surgery in the treatment of advanced-stage patients, including stage IIIB patients.
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Importantly, although current National Comprehensive Cancer Network guidelines endorse limited recommendations for surgical treatment for patients with advancedstage NSCLC, these guidelines are drawn from studies that have not adequately evaluated the heterogeneity among patients with advanced-stage NSCLC. Moreover, these studies do not reflect contemporary surgical outcomes using current minimally invasive surgical techniques and strategies to minimize the use of highly morbid pneumonectomy. 4, 16, 17 For example, in a randomized trial of induction chemotherapy followed by surgery or radiotherapy for patients with stage IIIA-N2 NSCLC, representing treatments given from 1994 to 2002, van Meerbeeck and colleagues 17 reported exploratory thoracotomy in 14%, pneumonectomy in 47%, and incomplete resection in 50% of patients. Therefore, it is not surprising that the authors observed no differences in OS between the surgical and radiotherapy cohorts. 17 Similarly, Albain and colleagues 16 compared induction chemotherapy plus radiation followed by surgery to induction chemotherapy plus definitive radiotherapy in a randomized trial of stage IIIA-N2 patients. These authors also found no significant difference in OS between the surgical and nonsurgical groups. However, this trial also was noted to have a high rate of pneumonectomy (34%), and 9% of patients underwent no or incomplete resection. In addition, their patient sample was heterogeneous, with 20% having 2 positive nodal stations and 2% having 3 positive nodal stations. Consequently, it is likely that patient heterogeneity and poor surgical outcomes did not allow for a fair comparison between surgically and nonsurgically treated groups as well as underestimate survival outcomes observed with surgery in a more contemporaneous cohort such as ours. These data should raise questions about the role of thoracic surgery for carefully selected patients with advanced-stage NSCLC in the future and suggest the need for randomized trials applying contemporary surgical techniques.
Because of the heterogeneous nature of patients with advanced-stage NSCLC and multiplicity of treatment options, clinical trials to assess the true therapeutic impact of surgery for these patients are likely prohibitively challenging to design and accrue. Yet, delivery of an effective treatment modality, including surgery, to an appropriately selected patient subset who will derive benefit is the cornerstone of personalized medicine. Unlike retrospective database analyses, which only allow for prediction of outcomes after treatment decisions have been made, we maintain that a significant strength of the SSS is its ability to be used prospectively to assess a patient's probability of both receiving surgical treatment and deriving improved OS. [18] [19] [20] Moreover, given its novel ability to be used prospectively, after further validation, the SSS may have a role in reducing treatment variation because it can be used by both surgeons and nonsurgeons to identify patients who may benefit from consideration for surgical treatment and/or enrollment into prospective clinical trials stratified by SSS. We do not contend that the SSS should be used as a dichotomous tool to decide who can and cannot undergo surgery as part of multimodality treatment. Rather, we believe it may help nonsurgeons identify additional patients who could be evaluated for surgery and that surgeons would provide the appropriate evaluation of surgical candidacy to include a physiologic assessment, tumor resectability, and assessment of disease burden, as per guidelines. 4 Multidisciplinary tumor boards and telehealth interventions could then be used to evaluate and extend surgical options to patients who might not otherwise be exposed. 21, 22 Despite its strengths, it is important to acknowledge the limitations of our analysis. The SSS is limited by the ongoing presence of unmeasured confounding variables. Because tumor resectability, pulmonary function, and smoking status are not captured in administrative datasets such as the NCDB, the SSS cannot definitively predict which patients will be appropriate for surgical resection. These factors may have biased our results in favor of surgery despite controlling for comorbidities using the Charlson index, which is the only available measure of performance status in the NCDB. In addition, disease burden and intent of resection are not currently captured in the NCDB and would impact the decision to offer therapeutic surgical resection to a patient. It is also likely that response to systemic treatment and molecular status of tumors were considered in surgical decisions, but there is no large dataset that currently capture these data or allow it to be analyzed. Therefore, future analyses incorporating these data will be important to validate our findings and thereby optimize personalized treatment for these patients.
In a manuscript that is heavily dependent on statistical analysis, we must acknowledge statistical limitations. Patients missing essential characteristics like the Charlson index or survival information (when needed) were omitted from the cohort before the statistical analysis, and we did not attempt to impute missing values because we believe it is reasonable to assume these data were missing at random. It is a limitation that we had to omit incomplete data and we cannot be certain that data was missing at random even though patients with missing survival information were evenly distributed across the surgery and nonsurgery groups and also SSS strata.
Although it is possible that there are patients with high SSS who are not candidates for surgical resection, it is also possible that the SSS will identify patients who will derive benefit from surgery but were previously not offered this modality. We acknowledge that our analysis using the SSS cannot fully eliminate the impact of selection bias on the survival outcomes observed, but the magnitude of the clinically and statistically significant survival differences between the groups, particularly when controlling for SSS, suggest that further exploration of the association of surgery with improved survival is warranted. In the era of increasingly effective systemic therapies, the incorporation of surgery into a careful multimodality treatment approach may improve disease control and OS beyond what can be attributed to selection bias alone.
CONCLUSIONS
The management of advanced-stage NSCLC is undergoing a paradigm shift, and patients whose prognosis was previously measured in months can now often be measured in years. We have derived an SSS that identifies factors that robustly predict selection for surgical management and OS in patients with stage IIIA, IIIB, and IV NSCLC. Therefore, our data suggest that the SSS may prove to be a valuable tool for clinicians to help identify patients who could potentially benefit from surgical evaluation in an era in which treatment options for advanced-stage NSCLC are expanding, but overall treatment nihilism appears to persist for lung cancer patients across all stages.
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